Comparison of the effect of dexmedetomidine and neostigmine on the heart rate during robotic-assisted atrial septal defect repair

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000036140

Enrollment

Unknown

Registered

2020-08-21

Start date

2020-08-16

Completion date

Unknown

Last updated

2020-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial septal defect

Interventions

Dexmedetomidine group:Begin pumping dexmedetomidine when the guide wire is inserted from the femoral vein

Neostigmine group:giving neostigmine at the beginning of cardiopulmonary bypass

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1) Aged < 65 years; 2) Atrial septal defect; 3) The surgical method is robot-assisted atrial septal defect repair with heart beating.

Exclusion criteria

Exclusion criteria: Liver and kidney dysfunction.

Design outcomes

Primary

Measure	Time frame
heart rate;Arterial blood oxygen partial pressure;	—

Countries

China

Contacts

Public ContactHuixuan Zhou

300 Guangzhou Road, Nanjing, Jiangsu

wenzhu123.zhou@163.com+86 13913884657

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026